Jaguar Health shareholders approve major equity issuances to C/M Capital, risking 40%+ dilution

Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read

Key Changes

• high

  Stockholders approved issuing over 19.99% of outstanding shares to C/M Capital under an equity line of credit agreement to be executed within 90 days, representing significant dilution to existing holders.

  Item 5.07: ELOC Agreement verify on EDGAR →
• high

  A second equity issuance to C/M Capital was approved involving Series P Non-Convertible Preferred Stock redeemable for common shares, potentially exceeding another 19.99% of outstanding stock.

  Item 5.07: Preferred Stock verify on EDGAR →
• low

  John Micek III was elected as Class II director for a three-year term through 2029, receiving 3.97 million votes for and 241,000 withheld.

  Item 5.07: Director Election verify on EDGAR →